Phosphorylation of the skeletal muscle (RyR1) and cardiac muscle (RyR2) ryanodine receptors has been reported to modulate channel activity. Abnormally high phosphorylation levels (hyperphosphorylation) 
Unless otherwise indicated, experiments were performed as described (33). Membrane fractions (25- In experiments using protein phosphatase (PP) treated SR, acid phosphatase (Sigma) was dialyzed for 5 h at 4ºC against sample buffer and membranes were subsequently incubated with phosphatase at 60 ìg protein/unit PP for 1 h at 37ºC. RyR2-2809 phosphorylation levels of treated and untreated samples were determined by immunoblot analysis using a phospho-RyR2-Ser2809-and de-phospho-RyR2-Ser2809 specific antibody (Badrilla, Leeds, UK). Development and analysis of western blots were performed as described under Co-immunoprecipitation except that 5% bovine serum albumin in Tris buffered saline (TBS) was used for blocking and primary antibody incubation medium and TBS with 0.05% Tween 20 was used as washing buffer.
Co-immunoprecipitation of RyRs and FKBPs -For immunoprecipitation experiments,
membranes (1-2 mg protein) were homogenized in ice-cold 20 mM NaPipes, pH 7.2 buffer containing 0.3 M sucrose, 1 M NaCl, 2.5% Triton X-100 and protease inhibitors (Complete choice protease inhibitor tablets, Roche) using a Teflon homogenizer. Following 10 min incubation on ice, samples were diluted with ice-cold water to 1.25% Triton X-100 and incubated on ice for an additional 20 min. Solubilized receptors were separated by centrifugation at 100,000 × g for 40 min, diluted with 20 mM NaPipes, pH 7.0 buffer containing 0.3 M sucrose, 5 mM DTT, 1.2 mM CaCl 2 and protease inhibitors (Complete choice protease inhibitor tablets, Roche) to 0.3% Triton X-100 and 125 mM NaCl, and incubated with mouse monoclonal antibody RyRD110 (1:10) raised against rabbit skeletal muscle RyR and mouse monoclonal antibody RyRC3-33 (1:10) raised against cardiac muscle RyR at 4ºC. After 12 h, anti-mouse IgG-agarose beads (Sigma) were added and the sample incubated for an additional 2 h.
Subsequently, beads were washed three times with 20 mM NaPipes, pH 7.0 buffer containing 0.3% Triton X-100 and 125 mM NaCl and once with phosphate buffered saline (PBS) to remove residual Triton X-100. Bound proteins were solubilized in SDS buffer at 37ºC for 15 min and separated on 3-15% gradient SDS polyacrylamide gels. Proteins in the top half of the gel (>60 kDa) were transferred in a cooled wet-chamber for 1 h at 400 mA and 12 h at 1000 mA onto a PDVF membrane (Millipore), and blocked with 5% milk and 0.05% Tween 20 in PBS. RyRs were detected using mAb RyRD110 and mAb RyRC3-33, both diluted to 1:10 with 5% milk and 0.05% Tween 20 in PBS. The bottom half of the gel was transferred in semi-dry chamber overnight at 50 mA onto PDVF, blocked with 5% milk and 0.05% Tween 20 in PBS and blotted with anti-FKBP antibody (Alexis) diluted to 1:2000 in 5% milk and 0.05% Tween 20 in PBS.
RyR and co-immunoprecipitated FKBP were detected using enhanced chemiluminescence (ECL) (Amersham Pharmacia Biotech) and proteins were quantified using Scientific Imaging System Kodak 1D 3.6. Data analysis -Results are given as means ± standard error (S.E.) with the number of experiments in parentheses. Significance of differences in the data (p<0.05) was determined using Student's t-test.
Calcium imaging

Results
We used site-directed mutagenesis to prepare skeletal and cardiac RyR mutants that carry an alanine or aspartic acid substitution at the conserved phosphorylation site, RyR1-Ser2843 and Similarly, we found that in immunoblots the expression level of FKBP12 exceeded that of FKBP12.6 (data not shown).
RyR expression levels were determined by Scatchard plot analysis. Transfection using RyR1 cDNA resulted in expression levels of 0. WT and mutant RyR2s co-expressed with FKBP12.6 were solubilized in Triton X-100 as described in Experimental Procedures and the non-solubilized material was removed by centrifugation. RyR2s in the total and supernatant fractions were immunoprecipitated using antiRyR2 antibody and analyzed by western blots for RyR2 ( Fig. 1A ) and FKBP12.6 (Fig. 1B) .
Immunoprecipitates of the total and supernatant fractions yielded immunoreactive bands for both Table 1 for RyR1 and in Table 2 for RyR2. P o values were determined using single-and multiple-channel recordings whereas only single-channel recordings were used for number of events, T o and T c calculations. Some differences were observed between the kinetic parameters of the WT-RyRs and their corresponding phosphorylation mutants, but none of these were significant. The K + -conducting WT-RyR2, RyR2-S2809A and RyR2-S2809D channels recorded at -20 mV holding potential (top panel of Table 2 ) were activated to a greater extent with 2 µM Ca 2+ on both sides of the bilayer and the open times were more than 10-fold greater than those of the RyR1 channels (top panel of Table 1 ). These isoform-dependent differences are a characteristic property of the two RyRs. caused no significant changes between mutant and WT receptors (Fig. 5B ).
We also considered the possibility that the recombinant RyR channels with a serine to aspartic acid substitution decreased the Ca 2+ content of HEK293 cells, by forming "leaky" Ca shows essentially identical Ca 2+ activation/Ca 2+ inactivation binding curves for cardiac SR membranes that were treated and not treated with acid phosphatase. Alkaline phosphatase treatment also was without significant effect on Ca 2+ -dependence of treated SR (data not shown).
Evidence for additional phosphorylation sites in RyR2 -We also explored the possibility that additional sites in RyR are phosphorylated. Mutant and WT cardiac receptors were expressed in the presence of 32 P i and isolated using a CaM-agarose batch purification protocol. Proteins retained on the beads were separated by 3-10% SDS-PAGE. Western blots of unlabeled samples showed that solubilized native and recombinant RyR2s bind to the CaM-agarose beads (Fig. 8A ).
Addition of 3 ìM CaM abolished binding, thereby confirming the specificity of the CaM and RyR interaction. Fig. 8B shows the silver stained gels of metabolically labeled WT-RyR2, RyR2-S2809A and RyR2-S2809D. RyR2s were bound in the presence and absence of 3 ìM CaM to correct for nonspecific binding. The corresponding autoradiogram is shown in Fig. 8C ;
WT and mutant RyR2s all incorporated 32 P i radioactivity. The amount of radioactivity in the RyR band was measured in a scintillation counter, normalized for the RyR2 content as determined by the silver staining and western blot signals, and corrected for 32 P background counts. The combined results from two independent experiments are shown in Fig. 8D . The finding of significant 32 P i incorporation into the cardiac phosphorylation mutants suggests that
RyR2 is phosphorylated at additional, so far uncharacterized phosphorylation sites. We note that in our experiments no attempt was made to activate CaMK or PKA which could have altered the extent of phosphorylation of Ser2809 relative to the additional sites.
Discussion
Protein phosphorylation is a fundamental mechanism by which kinases and phosphatases regulate a wide variety of biological processes. In striated muscle, protein kinases and phosphatases modulate both contraction and relaxation by phosphorylating and dephosphorylating numerous SR proteins that include the lumenal Ca 2+ binding protein calsequestrin (37), the Ca 2+ pump (38), its regulatory protein phospholamban (39), the RyR associated proteins triadin (40,41) and sorcin (42), and the Ca 2+ release channel/ryanodine receptor (11) . Changes in the phosphorylation levels are of interest due to the possibility that these contribute to an impaired SR and contractile function during heart failure. PKA and CaMKII phosphorylation of phospholamban results in an increased Ca 2+ -ATPase activity (39).
with other cellular changes, has been suggested as one possible mechanism leading to heart failure (25, 26) . A second proposed mechanism is that PKA-mediated hyper-phosphorylation of a conserved serine, Ser2843 in the skeletal RyR and Ser2809 in cardiac RyR, contributes to an impaired SR and aberrant contractile function during heart failure (9, 23) . Following acute ischemic/reperfusion decreased RyR2 phosphorylation levels have been observed (43). In this study, we prepared two skeletal muscle and cardiac muscle RyR mutants to test the hypothesis that phosphorylation of RyR1-Ser2843 and RyR2-Ser2809 modifies the intrinsic channel properties of the two receptor isoforms.
RyRs are known to be regulated by a large number of exogenous and endogenous effectors and to undergo various post-translational modifications, including phosphorylation. The cytoplasmic assembly makes up 80% of the entire channel and contains many conserved, potential phosphorylation sites. One of these sites, RyR1-Ser2843 and the corresponding serine in the cardiac receptor, RyR2-Ser2809, were phosphorylated by cAMP-and CaM-dependent protein kinases (12, 14) . However, the presence of additional phosphorylation sites is likely, as
CaMKII has been shown to phosphorylate one or more threonine residues in RyR (14) . In support of these findings are several studies observing different functional effects for PKA and Representative current histograms derived from 2 min recordings in the presence 1 mM ATP and 100 nM free Ca 2+ with 10 mM lumenal Ca 2+ as conducting ion. Single channel currents shown as downward deflections from the closed levels (C --) were recorded as in Fig. 2. (B) Representative amplitude histograms derived from 2 min recordings in the presence 1 mM ATP and 100 nM free Ca 2+ with 10 mM lumenal Ca 2+ as conducting ion. 
